On 2 April, the German-Swiss newspaper TagesWoche published an article about Novartis' decision to name Shannon Klinger chief of ethics and compliance and elevate the function to be part of the executive board following concerns raised about its patent policy and access to medicine as well as environmental impacts. We invited Novartis to respond to the TagesWoche article and asked how the company mitigates the social and environmental impacts of its business practices; response provided below. 

Note: TagesWoche article only available in German.